Efficient biopharmaceutical process development relies on the quality-by-design (QbD) paradigm. QbD is a scientific, risk-based proactive approach to drug development that aims to have a full understanding of how the process and product are related. This knowledge is gained by process analytical technology (PAT). Stephen Craven and Ulrike Becken at Eppendorf deal with upstream bioprocess interrogation and intensification.